RPAM
RGNX icon

Rhenman & Partners Asset Management’s Regenxbio RGNX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-75,000
Closed -$3.07M – 94
2019
Q4 		$3.07M Buy
+75,000
New +$2.96M 0.34% 77

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Rhenman & Partners Asset Management's RGNX Position: Q1 2020 in Review

Rhenman & Partners Asset Management sold out of Regenxbio (RGNX) in Q1 2020, closing a stake of 75,000 shares — an estimated $3.07M sold.

Rhenman & Partners Asset Management first reported a position in RGNX in Q4 2019 and held it in 1 quarter. The position peaked at $3.07M in Q4 2019. 170 funds tracked by Wall St. Rank hold RGNX as of Q1 2020.

  • Rhenman & Partners Asset Management reported no remaining Regenxbio position as of Q1 2020 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 75,000 Regenxbio shares in Q1 2020, an estimated $3.07M.
  • Rhenman & Partners Asset Management first reported a position in Regenxbio in Q4 2019 and held it in 1 quarter.
  • Rhenman & Partners Asset Management's Regenxbio position peaked at $3.07M in Q4 2019.
  • 170 funds tracked by Wall St. Rank held Regenxbio as of Q1 2020.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2020, filed 16 Apr 2020.